Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis - Takeaways - MDSpire

Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis

  • By

  • Jiani Chen

  • Tong Sun

  • Weili Luo

  • Chengyang Cao

  • Jiaqin Xu

  • Jiaxi Chen

  • June 4, 2026

  • 0 min

Share

  • 1

    This study analyzed plasma metabolomic and lipidomic profiles in rheumatoid arthritis (RA) to identify biomarkers for treatment response.

  • 2

    A total of 2,279 metabolites and 2,987 lipids were annotated, with 22 metabolites and lipids linked to RA risk identified through statistical analysis.

  • 3

    Twelve core features associated with treatment non-response were identified, including specific lipids and drug-related metabolites.

  • 4

    Machine learning models using these features demonstrated promising performance in distinguishing treatment-responsive from non-responsive RA patients.

  • 5

    The findings suggest significant metabolic alterations in RA, indicating potential biomarkers for predicting treatment response and disease management.

Original Source(s)

Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis

  • by Jiani Chen, Tong Sun, Weili Luo, Chengyang Cao, Jiaqin Xu, Jiaxi Chen

  • June 4, 2026

Related Content

An explainable predictive machine learning model of osteopenia for perimenopausal women based on clinical data: a retrospective single-center study

Medical Oddities: Prayer for Pain?

This week’s research collection showed that biology, behavior, and environment often intersect in unexpected ways.

CAA Use Tied to Higher Arthroplasty Risk

In a UK cohort, patients with osteoarthritis who initiated centrally acting analgesics had a higher hazard of knee or hip replacement than those who initiated SSRIs, though residual confounding by pain severity remains a key limitation.